Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INMUNOCEM
- Development stage
- Phase 2
- Lead developer
- Inmunocel
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
INMUNOCEM appears to be a brand or product name associated with cellular therapies, specifically mesenchymal stem cell (MSC) transplantation, used as an adjuvant therapy for various chronic and degenerative diseases. The therapy is positioned as an alternative treatment for conditions such as autoimmune diseases (e.g., systemic lupus erythematosus), inflammatory bowel disease (e.g., Crohn's disease), neurological disorders (e.g., autism), and cardiovascular events (e.g., myocardial infarction). The mechanism of action involves the immunomodulatory and regenerative properties of mesenchymal stem cells, which can modulate immune responses, reduce inflammation, and promote tissue repair. The developer and provider of these protocols is Inmunocel S.p.A., operating under the brand Inmunocell[1][3][4].
- Brand names
- INMUNOCEM
- Other names
- INMUNOCEM
Beyond the preview
Go deeper on INMUNOCEM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INMUNOCEM.